ProGRP作为表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗后非小细胞肺癌向小细胞肺癌转化的早期预测标志物。
ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment.
作者信息
Kato Yasuhiro, Tanaka Yosuke, Hino Mitsunori, Gemma Akihiko
机构信息
Respiratory Disease Center, Chiba Hokusoh Hospital, Nippon Medical School, Chiba, Japan.
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
出版信息
Respir Med Case Rep. 2019 Apr 13;27:100837. doi: 10.1016/j.rmcr.2019.100837. eCollection 2019.
We report a case of non-small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advanced NSCLC. After he was introduced afatinib, his tumor had been reduced by the treatment. However, plasma pro-gastrin-releasing peptide (ProGRP) became higher with disease progression, and SCLC was detected at the second biopsy. It is suggested that elevation of plasma ProGRP level before EGFR-TKI therapy is useful for predicting EGFR-mutant NSCLC to SCLC transformation.
我们报告了1例表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗后从非小细胞肺癌（NSCLC）转化为小细胞肺癌（SCLC）的病例。该患者为男性，被诊断为EGFR突变的晚期NSCLC。在接受阿法替尼治疗后，其肿瘤有所缩小。然而，随着疾病进展，血浆胃泌素释放肽前体（ProGRP）升高，二次活检时检测到SCLC。提示EGFR-TKI治疗前血浆ProGRP水平升高有助于预测EGFR突变的NSCLC向SCLC转化。
Zotero 插件